dc.contributor.author |
Harakeh S. |
dc.contributor.author |
Abu-El-Ardat K. |
dc.contributor.author |
Diab-Assaf M. |
dc.contributor.author |
Niedzwiecki A. |
dc.contributor.author |
El-Sabban M. |
dc.contributor.author |
Rath M. |
dc.contributor.editor |
|
dc.date |
Mar-2008 |
dc.date.accessioned |
2017-10-03T15:43:40Z |
dc.date.available |
2017-10-03T15:43:40Z |
dc.date.issued |
2008 |
dc.identifier |
10.1007/s12032-007-0036-6 |
dc.identifier.isbn |
|
dc.identifier.issn |
13570560 |
dc.identifier.uri |
http://hdl.handle.net/10938/12573 |
dc.description.abstract |
The objective of this study is to evaluate the efficacy of epigallocatechin gallate against ATL cells. The anti-proliferative and pro-apoptotic effects of EGCG were evaluated in HTLV-1-positive and -negative cells. EGCG exhibited a marked decrease in proliferation of ATL cells at 96 h of treatment. The results indicated that TGF-α was down-regulated whereas levels of TGF-β2 increased. Cell cycle distribution analysis revealed an increase in cells in the pre-G1 phase which was confirmed by ELISA. The results on proteins showed an up-regulation of p53, Bax and p21 protein levels while the levels of Bcl-2α were down-regulated. © 2007 Humana Press Inc. |
dc.format.extent |
|
dc.format.extent |
Pages: (30-39) |
dc.language |
English |
dc.publisher |
TOTOWA |
dc.relation.ispartof |
Publication Name: Medical Oncology; Publication Year: 2008; Volume: 25; no. 1; Pages: (30-39); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
Epigallocatechin-3-gallate induces apoptosis and cell cycle arrest in HTLV-1-positive and -negative leukemia cells |
dc.type |
Article |
dc.contributor.affiliation |
Harakeh, S., Biology Department, American University of Beirut, Beirut 11-0236, Lebanon |
dc.contributor.affiliation |
Abu-El-Ardat, K., Biology Department, American University of Beirut, Beirut 11-0236, Lebanon |
dc.contributor.affiliation |
Diab-Assaf, M., Biology Department, American University of Beirut, Beirut 11-0236, Lebanon |
dc.contributor.affiliation |
Niedzwiecki, A., Dr. Rath Research Insitute, Santa Clara, CA, United States |
dc.contributor.affiliation |
El-Sabban, M., Human Morphology Department, American University of Beirut, Beirut 11-0236, Lebanon |
dc.contributor.affiliation |
Rath, M., Dr. Rath Research Insitute, Santa Clara, CA, United States |
dc.contributor.authorAddress |
Harakeh, S.; Biology Department, American University of Beirut, Beirut 11-0236, Lebanon; email: sharakeh@gmail.com |
dc.contributor.authorCorporate |
University: American University of Beirut; Faculty: Faculty of Arts and Sciences; Department: Biology; |
dc.contributor.authorDepartment |
Biology |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
sharakeh@gmail.com |
dc.contributor.faculty |
Faculty of Arts and Sciences |
dc.contributor.authorInitials |
Harakeh, S |
dc.contributor.authorInitials |
Abu-El-Ardat, K |
dc.contributor.authorInitials |
Diab-Assaf, M |
dc.contributor.authorInitials |
Niedzwiecki, A |
dc.contributor.authorInitials |
El-Sabban, M |
dc.contributor.authorInitials |
Rath, M |
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
Harakeh, S (reprint author), Amer Univ Beirut, Dept Biol, Beirut 110236, Lebanon. |
dc.contributor.authorResearcherID |
Harakeh, Steve-K-5709-2012 |
dc.contributor.authorUniversity |
American University of Beirut |
dc.description.cited |
Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006-abbi.2000.1742; Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182-blood-2001-12-0372; BAZARBACHI A, 1996, J ACQ IMMUN DEF R S1, V13, P5186; Cerwenka A, 1996, J IMMUNOL, V156, P459; Chen WJ, 1998, J EXP MED, V188, P1849, DOI 10.1084-jem.188.10.1849; Dotto G P, 2000, BIOCHIM BIOPHYS ACTA, V1471, pM43; Dupont S, 2004, CANCER LETT, V213, P129, DOI 10.1016-j.canlet.2004.06.008; Erba D, 1999, J NUTR, V129, P2130; Fujiki H, 1998, MUTAT RES-FUND MOL M, V402, P307, DOI 10.1016-S0027-5107(97)00310-2; GESSAIN A, 1996, HUMAN T CELL LYMPHOT, P33; Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006-taap.1999.8885; Gupta S, 2003, ARCH BIOCHEM BIOPHYS, V410, P177, DOI 10.1016-S0003-9861(02)00668-9; Hare Y, 2001, GREEN TEA HLTH BENEF; Haupt S, 2004, SEMIN CANCER BIOL, V14, P244, DOI 10.1016-j.semcancer.2004.04.003; Hayakawa S, 2001, BIOCHEM BIOPH RES CO, V285, P1102, DOI 10.1006-bbrc.2001.5293; Heiser D, 2004, EXP GERONTOL, V39, P1125, DOI 10.1016-j.exger.2004.04.011; HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056-NEJM199506293322604; HINUMA Y, 1985, PNAS, V66, P1371; Hsu TC, 2001, CANCER GENET CYTOGEN, V124, P169, DOI 10.1016-S0165-4608(00)00337-X; Inman GJ, 2000, J IMMUNOL, V165, P2500; Javelaud D, 2004, INT J BIOCHEM CELL B, V36, P1161, DOI 10.1016-S1357-2725(03)00255-3; Kanai M, 2001, GASTROENTEROLOGY, V121, P56, DOI 10.1053-gast.2001.25544; KAPLAN JE, 1993, REV MED VIROL, V3, P137, DOI 10.1002-rmv.1980030304; Kawai K, 2003, J ALLERGY CLIN IMMUN, V112, P951, DOI [10.1067-mai.2003.1756, 10.1016-S0091-6749(03)02007-4]; Kuo PL, 2003, J BIOMED SCI, V10, P219, DOI 10.1159-000068711; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074-jbc.M206786200; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146-annurev.immunol.16.1.137; Li HC, 2000, JPN J CANCER RES, V91, P34; Lozano G, 2005, J PATHOL, V205, P206, DOI 10.1002-path.1704; Lu X, 2005, CURR OPIN GENET DEV, V15, P27, DOI 10.1016-j.gde.2004.12.008; Macchi B, 1997, J GEN VIROL, V78, P1007; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038-sj.onc.1203285; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016-j.dnarep.2004.03.027; Mitscher LA, 1997, MED RES REV, V17, P327, DOI 10.1002-(SICI)1098-1128(199707)17:4327::AID-MED23.0.CO;2-Y; Nihal M, 2005, INT J CANCER, V114, P513, DOI 10.1002-ijc.20785; Otsuka T, 1998, LIFE SCI, V63, P1397, DOI 10.1016-S0024-3205(98)00406-8; Patil S, 2000, J BIOL CHEM, V275, P38363, DOI 10.1074-jbc.M004861200; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006-jmbi.1999.2640; Roomi MW, 2005, IN VIVO, V19, P179; Roomi MW, 2005, MED ONCOL, V22, P129, DOI 10.1385-MO:22:2:129; Roomi MW, 2005, ONCOL REP, V13, P253; Roy M, 2003, MUTAT RES-FUND MOL M, V523, P33, DOI 10.1016-S0027-5107(02)00319-6; SAEKI K, 2000, J BIOL CHEM, V272, P3; Sanchez-Capelo A, 2005, CYTOKINE GROWTH F R, V16, P15, DOI 10.1016-j.cytogtf.2004.11.002; Szeto YT, 2002, FREE RADICAL RES, V36, P113, DOI 10.1080-10715760290001227; Wang YC, 2002, AMINO ACIDS, V22, P131, DOI 10.1007-s007260200002; Wolfraim LA, 2004, J IMMUNOL, V173, P3093; Yang CS, 2004, J NUTR, V134, p3181S; Yang CS, 1998, EXP LUNG RES, V24, P629; Zhang J, 2001, VIRUS RES, V78, P67, DOI 10.1016-S0168-1702(01)00285-4 |
dc.description.citedCount |
22 |
dc.description.citedTotWOSCount |
24 |
dc.description.citedWOSCount |
22 |
dc.format.extentCount |
10 |
dc.identifier.articleNo |
|
dc.identifier.coden |
MONCE |
dc.identifier.pubmedID |
18188712 |
dc.identifier.scopusID |
42949123220 |
dc.identifier.url |
|
dc.publisher.address |
999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA |
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
Med. Oncol. |
dc.relation.ispartOfIssue |
1 |
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Medical Oncology |
dc.relation.ispartofPubTitleAbbr |
Med. Oncol. |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
25 |
dc.source.ID |
WOS:000252280800004 |
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
Apoptosis |
dc.subject.otherAuthKeyword |
Epigallocatechin-3- gallate (EGCG) |
dc.subject.otherAuthKeyword |
Human T-cell Lymphotrophic Virus-1 (HTLV-1) |
dc.subject.otherAuthKeyword |
p21 |
dc.subject.otherAuthKeyword |
p53 |
dc.subject.otherAuthKeyword |
Transforming Growth Factor (TGF) |
dc.subject.otherChemCAS |
epigallocatechin gallate, 989-51-5 |
dc.subject.otherChemCAS |
protein bcl 2, 219306-68-0 |
dc.subject.otherChemCAS |
protein p21, 85306-28-1 |
dc.subject.otherChemCAS |
catechin, 13392-26-2, 154-23-4 |
dc.subject.otherChemCAS |
transforming growth factor, 76057-06-2 |
dc.subject.otherChemCAS |
Catechin, 154-23-4 |
dc.subject.otherChemCAS |
epigallocatechin gallate, 989-51-5 |
dc.subject.otherChemCAS |
RNA, Messenger |
dc.subject.otherChemCAS |
Transforming Growth Factors, 76057-06-2 |
dc.subject.otherIndex |
epigallocatechin gallate |
dc.subject.otherIndex |
protein Bax |
dc.subject.otherIndex |
protein bcl 2 |
dc.subject.otherIndex |
protein p21 |
dc.subject.otherIndex |
protein p53 |
dc.subject.otherIndex |
transforming growth factor alpha |
dc.subject.otherIndex |
transforming growth factor beta2 |
dc.subject.otherIndex |
catechin |
dc.subject.otherIndex |
drug derivative |
dc.subject.otherIndex |
epigallocatechin gallate |
dc.subject.otherIndex |
messenger RNA |
dc.subject.otherIndex |
transforming growth factor |
dc.subject.otherIndex |
antineoplastic activity |
dc.subject.otherIndex |
apoptosis |
dc.subject.otherIndex |
article |
dc.subject.otherIndex |
cell cycle arrest |
dc.subject.otherIndex |
cell cycle G1 phase |
dc.subject.otherIndex |
cell proliferation |
dc.subject.otherIndex |
controlled study |
dc.subject.otherIndex |
cytotoxicity |
dc.subject.otherIndex |
down regulation |
dc.subject.otherIndex |
drug efficacy |
dc.subject.otherIndex |
enzyme linked immunosorbent assay |
dc.subject.otherIndex |
flow cytometry |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
human cell |
dc.subject.otherIndex |
Human T cell leukemia virus 1 |
dc.subject.otherIndex |
leukemia cell |
dc.subject.otherIndex |
priority journal |
dc.subject.otherIndex |
protein expression |
dc.subject.otherIndex |
T cell leukemia |
dc.subject.otherIndex |
upregulation |
dc.subject.otherIndex |
apoptosis |
dc.subject.otherIndex |
cell cycle |
dc.subject.otherIndex |
drug effect |
dc.subject.otherIndex |
genetics |
dc.subject.otherIndex |
Human T cell leukemia virus 1 |
dc.subject.otherIndex |
isolation and purification |
dc.subject.otherIndex |
pathology |
dc.subject.otherIndex |
t cell leukemia lymphoma |
dc.subject.otherIndex |
tumor cell line |
dc.subject.otherIndex |
virology |
dc.subject.otherIndex |
Apoptosis |
dc.subject.otherIndex |
Catechin |
dc.subject.otherIndex |
Cell Cycle |
dc.subject.otherIndex |
Cell Line, Tumor |
dc.subject.otherIndex |
Cell Proliferation |
dc.subject.otherIndex |
Enzyme-Linked Immunosorbent Assay |
dc.subject.otherIndex |
Flow Cytometry |
dc.subject.otherIndex |
Human T-lymphotropic virus 1 |
dc.subject.otherIndex |
Humans |
dc.subject.otherIndex |
Leukemia-Lymphoma, Adult T-Cell |
dc.subject.otherIndex |
RNA, Messenger |
dc.subject.otherIndex |
Transforming Growth Factors |
dc.subject.otherKeywordPlus |
GREEN TEA EXTRACT |
dc.subject.otherKeywordPlus |
PROSTATE CARCINOMA-CELLS |
dc.subject.otherKeywordPlus |
HUMAN T-CELLS |
dc.subject.otherKeywordPlus |
VIRUS TYPE-I |
dc.subject.otherKeywordPlus |
TGF-BETA |
dc.subject.otherKeywordPlus |
GROWTH-INHIBITION |
dc.subject.otherKeywordPlus |
ASCORBIC-ACID |
dc.subject.otherKeywordPlus |
CONSTITUENT (-)-EPIGALLOCATECHIN-3-GALLATE |
dc.subject.otherKeywordPlus |
KAPPA-B |
dc.subject.otherKeywordPlus |
P53 |
dc.subject.otherWOS |
Oncology |